CALIFORNIA PACIFIC MEDICAL CENTER
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 050047
- Received
- $1,656,051 in 68 records, 2024 ($44,085 general, $1,611,966 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 22 | $44,085 |
| 2024 | Research payment | 46 | $1,611,966 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 12 | $1,340,992 | 2024 |
| ModernaTX, Inc. | 6 | $113,019 | 2024 |
| Genentech, Inc. | 9 | $79,727 | 2024 |
| Stryker Corporation | 17 | $37,015 | 2024 |
| PTC Therapeutics, Inc. | 4 | $30,391 | 2024 |
| Regeneron Pharmaceuticals, Inc. | 5 | $18,828 | 2024 |
| ABBVIE INC. | 4 | $17,412 | 2024 |
| Boston Scientific Corporation | 4 | $6,108 | 2024 |
| Medtronic, Inc. | 2 | $5,984 | 2024 |
| Novartis Pharmaceuticals Corporation | 1 | $2,500 | 2024 |
| GT Medical Technologies, Inc | 1 | $2,000 | 2024 |
| Micro-tech Endoscopy USA, Inc. | 2 | $1,707 | 2024 |
| Medline Industries LP | 1 | $362 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 46 | $1,611,966 |
| Long term medical supply or device loan | 19 | $38,722 |
| Space rental or facility fees (teaching hospital only) | 2 | $5,000 |
| Debt forgiveness | 1 | $362 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $541,826 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologo | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $282,985 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $43,197 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $16,898 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $11,145 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 and Lenvatin | 2024 |
| 2024-12-31 | Stryker Corporation | $6,533 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,438 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Mo | 2024 |
| 2024-12-31 | Stryker Corporation | $3,785 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,785 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,686 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,234 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $3,143 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2024 |
| 2024-12-31 | Stryker Corporation | $2,788 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,230 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,065 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,627 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,511 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $958 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $958 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $944 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $744 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $719 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $719 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $719 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Medline Industries LP | $362 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Medtronic, Inc. | $1,150 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2024 |
| 2024-11-06 | Merck Sharp & Dohme LLC | $127,506 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#Sentinel Lymph Nodes# Immune Response to Melanoma and Implications to Survival and Therapy Outcomes with pemb | 2024 |
| 2024-10-20 | Micro-tech Endoscopy USA, Inc. | $853 | Long term medical supply or device loan (26 payments) | In-kind items and services | EL27-Compact Electrohydraulic Lithotripter Device, Gastroenterology | 2024 | |
| 2024-10-20 | Micro-tech Endoscopy USA, Inc. | $853 | Long term medical supply or device loan (26 payments) | In-kind items and services | HD Digital Controller for eyeMAX PB Device, Gastroenterology | 2024 | |
| 2024-10-16 | ModernaTX, Inc. | $19,051 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2024 | |
| 2024-10-16 | ModernaTX, Inc. | $8,243 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2024 | |
| 2024-10-16 | ModernaTX, Inc. | $3,645 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2024 | |
| 2024-10-09 | Regeneron Pharmaceuticals, Inc. | $14,673 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2024 |
| 2024-10-09 | Regeneron Pharmaceuticals, Inc. | $2,497 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2024 |
| 2024-10-01 | GT Medical Technologies, Inc | $2,000 | Research payment | Cash or cash equivalent | GammaTile Device, KXK | GTM-101 | 2024 |
| 2024-09-30 | Merck Sharp & Dohme LLC | $1,972 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Mo | 2024 |
| 2024-09-25 | ModernaTX, Inc. | $3,280 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2024 | |
| 2024-09-18 | Regeneron Pharmaceuticals, Inc. | $1,100 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2024 |
| 2024-09-18 | Regeneron Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2024 |
| 2024-09-04 | ABBVIE INC. | $1,075 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co | 2024 | |
| 2024-08-05 | PTC Therapeutics, Inc. | $3,804 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2024 | |
| 2024-07-23 | Boston Scientific Corporation | $1,221 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-07-09 | Genentech, Inc. | $34,973 | Research payment | Cash or cash equivalent | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | 2024 | |
| 2024-07-02 | Regeneron Pharmaceuticals, Inc. | $57 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2024 |
| 2024-06-26 | ModernaTX, Inc. | $51,236 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2024 | |
| 2024-06-25 | Boston Scientific Corporation | $1,221 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-06-12 | Medtronic, Inc. | $4,834 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2024 |
| 2024-06-06 | ABBVIE INC. | $1,719 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co | 2024 | |
| 2024-06-05 | PTC Therapeutics, Inc. | $10,239 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2024 | |
| 2024-05-27 | Merck Sharp & Dohme LLC | $149,799 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2024 |
| 2024-05-22 | Merck Sharp & Dohme LLC | $155,579 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 and Lenvatin | 2024 |
| 2024-05-09 | ABBVIE INC. | $13,773 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co | 2024 | |
| 2024-04-22 | Boston Scientific Corporation | $1,221 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-04-19 | Merck Sharp & Dohme LLC | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-04-19 | Novartis Pharmaceuticals Corporation | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KISQALI Drug, Oncology | 2024 | |
| 2024-04-03 | PTC Therapeutics, Inc. | $10,714 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2024 | |
| 2024-04-03 | PTC Therapeutics, Inc. | $5,633 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2024 | |
| 2024-03-07 | ABBVIE INC. | $843 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in | 2024 | |
| 2024-03-06 | Genentech, Inc. | $14,800 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2024 | |
| 2024-03-06 | Genentech, Inc. | $8,773 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2024 | |
| 2024-03-06 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2024 | |
| 2024-03-06 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2024 | |
| 2024-03-06 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2024 | |
| 2024-03-06 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | 2024 | |
| 2024-02-20 | Genentech, Inc. | $4,240 | Research payment | Cash or cash equivalent | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | 2024 | |
| 2024-02-02 | ModernaTX, Inc. | $27,562 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2024 | |
| 2024-01-22 | Boston Scientific Corporation | $2,443 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-01-11 | Genentech, Inc. | $10,441 | Research payment | Cash or cash equivalent | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments